QLS2309 for CD70-positive blood cancers that returned
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called QLS2309 for people with certain blood cancers that have come back or not responded to other treatments. The drug targets a protein called CD70 on the cancer cells, and this study aims to find the safest dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a blood cancer that has come back after treatment or hasn't responded to treatment, and your cancer cells have a protein called CD70 on them.
- You must be well enough to be up and about at least half the day (ECOG score 0-2).
- You cannot have had a CD70-targeted treatment before.
- You cannot have active infections like hepatitis B, C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, QLS2313, for people with certain types of blood cancer (B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma) that have not gotten better with other treatments. The goal is to see if the drug is safe and works.
This trial tests a new drug called QLS5133 for people with advanced solid tumors that have not responded to other treatments. The drug is given alone, and the study aims to see if it is safe and effective.
This trial tests a new drug, QLS5132, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial tests a new drug called QL1706 for people with advanced liver cancer that has worsened after a previous immunotherapy treatment. The goal is to see if it can help slow down the cancer.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
This trial tests a new combination of drugs (QLC5513 and QL1706) for people with advanced or metastatic solid tumors that cannot be removed by surgery or radiation. The goal is to see if this combination is safe and effective.
Hear when a new Relapsed or Refractory Hematologic Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.